Factors Influencing Arteriovenous Fistula Dysfunction in Japanese Patients on Chronic Hemodialysis

Abstract

Arteriovenous fistula dysfunction is a constant problem in chronic hemodialysis patients. We investigated the factors influencing fistula dysfunction in 184 patients on chronic hemodialysis. Stepwise regression analysis and Cox proportional hazards model were used to assess the relationship between fistula dysfunction and age, sex, duration of hemodialysis, diabetes mellitus, hematocrit, serum creatinine, blood urea nitrogen, KW, prothrombin time, blood pressure, anticoagulant therapy, dose of erythropoietin, calcium channel blocker therapy, and angiotensin-converting enzyme inhibitor therapy. Fistula dysfunction showed a significant relationship with a low systolic blood pressure, a low hematocrit, the presence of diabetes mellitus, and angiotensin-converting enzyme inhibitor therapy. These results suggested that treatment with angiotensin-converting enzyme inhibitors may help to prevent fistula dysfunction.

Keywords

Fistula dysfunction Angiotensin-converting enzyme inhibitors Hemodialysis

Get full access to this article

View all access options for this article.

References

De Marchi

, Falleti

, Giacomello

. Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. J Am Soc Nephrol 1996; 7: 1169–77.

Goldwasser

, Avram

M.M.

, Collier

J.T.

, Michel

M.A.

, Gusik

S.A.

, Mittman

Correlates of vascular access occlusion in hemodialysis.

Am J Kidney Dis 1994; 24: 785–94.

Fan

P-Y

, Schwab

S.J.

Vascular access: concepts for the 1990s.

J Am Soc Nephrol 1992; 3: 1–11.

Diskin

C.J.

, Stokes

T.J.

Jr. , Pennell

A.T.

Pharmacologic interventions to prevent hemodialysis vascular access thrombosis.

Nephron 1993; 64: 1–26.

Diskin

C.J.

, Stokes

T.J.

, Thomas

S.G.

. An analysis of the effect of routine medications on hemodialysis vascular access survival. Nephron 1998; 78: 365–8.

Ray

P.E.

, Bruggeman

L.A.

, Horikoshi

, Aguilera

, Klotman

P.E.

Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors.

Kidney Int 1994; 45: 177–84.

Cox

D.R.

Regression models and life tables (with discussion).

J R Stat Soc Series B 1972; 34: 187–220.

Schwab

S.J.

, Raymond

J.R.

, Saeed

, Newman

G.E.

, Dennis

P.A.

, Bollinger

R.R.

Prevention of hemodialysis fistula thrombosis: early detection of venous stenoses.

Kidney Int 1989; 36: 707–11

Beathard

G.A.

Percutaneous transvenous angioplasty in the treatment of vascular access stenosis.

Kidney Int 1992; 42: 1390–6

10.

Windus

D.W.

, Jendrisak

M.D.

, Delmez

J.A.

Prosthetic fistula survival and complications in hemodialysis patients: effects of diabetes and age.

Am J Kidney Dis 1992; 19: 448–52.

11.

Zusmann

R.M.

Renin- and non-renin-mediated antihypertensive actions of converting enzyme inhibitors.

Kidney Int 1984; 25: 969–83.

12.

Anderson

P.W.

, Zhang

X.Y.

, Tian

. Insulin and angiotensin II are additive in stimulating TGF-ß1 and matrix mRNA in mesangial cells. Kidney Int 1996; 50: 745–53.

13.

Anderson

P.W.

, Do

Y.S.

, Hsueh

W.A.

Angiotensin II causes mesangial cell hypertrophy.

Hypertension 1993; 21: 29–35.

14.

Kagami

, Border

W.A.

, Miller

D.E.

, Noble

N.A.

Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-ß expression in rat glomerular mesangial cells.

J Clin Invest 1994; 93: 2431–7.

15.

Pfeffer

M.A.

, Braunwald

, Moye

L.A.

. Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669–77.

16.

Cattran

D.C.

, Greenwood

, Ritchie

Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy.

Am J Kidney Dis 1994; 23: 247–54.

17.

Lewis

E.J.

, Hunsicker

L.G.

, Bain

R.P.

, Rohde

R.D.

The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy.

N Engl J Med 1993; 11: 1456–62.